Research peptides are not approved for human use in most countries including India. This page is for educational purposes only. Consult a physician before use.
What is SS-31?
SS-31 (D-Arg-2'6'-dimethylTyr-Lys-Phe-NH2), also known as Elamipretide, Bendavia, or MTP-131, is a synthetic tetrapeptide designed by Hazel Szeto and Peter Schiller — hence "SS" peptides. It belongs to a class of Szeto-Schiller (SS) peptides specifically engineered to concentrate in the inner mitochondrial membrane (IMM) and protect cardiolipin.
The alternating cationic (Arg, Lys) and aromatic (dimethylTyr, Phe) amino acids give SS-31 its unique ability to penetrate cell membranes and concentrate selectively in the IMM — where it achieves concentrations 1,000-fold higher than in cytoplasm.
The Cardiolipin Hypothesis of Aging
Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane. It plays several critical roles:
- Structural scaffold for the cristae — the highly folded IMM structures that maximize the surface area for the electron transport chain (ETC)
- Directly supports the activity of all five ETC complexes and ATP synthase
- Regulates mitochondrial fission/fusion dynamics
- Regulates apoptosis via cytochrome c release
With aging and mitochondrial disease, cardiolipin content decreases and its fatty acid composition changes (losing linoleic acid, becoming more vulnerable to oxidation). Cardiolipin peroxidation leads to cristae disruption, ETC dysfunction, increased ROS generation, and ultimately cellular energy failure — a key mechanism of mitochondrial aging.
SS-31 directly binds cardiolipin through electrostatic and hydrophobic interactions, preventing its oxidation and maintaining the structural integrity of the IMM. This is a mechanistically unique intervention — no other known compound specifically protects cardiolipin.
Preclinical Evidence
The animal model data for SS-31 is extensive and impressive:
- Improves mitochondrial function in aged mouse hearts, skeletal muscle, and kidneys
- Reduces cardiac ischemia/reperfusion injury significantly in multiple animal models
- Improves exercise tolerance in old mice to levels approaching young mice
- Reduces glomerular damage in diabetic kidney disease models
- Improves mitochondrial ultrastructure (cristae morphology visible on electron microscopy)
Clinical Trial History
| Trial | Indication | Phase | Primary Outcome |
|---|---|---|---|
| MMAD trial | Heart failure with reduced EF | Phase III | Primary endpoint not met; secondary functional endpoints positive |
| SPIRO trial | Diabetic kidney disease | Phase II | Positive signals for eGFR preservation |
| EMBRACE STEMI | Acute MI reperfusion injury | Phase II | Favorable trend, not statistically significant |
| PIROUETTE trial | Heart failure with preserved EF | Phase II | Positive for exercise capacity improvement |
The MMAD Phase III trial is significant even though its primary endpoint was not met. Secondary endpoints showed meaningful functional improvements in heart failure patients. The safety profile was excellent — SS-31 is well tolerated in humans. The pharmaceutical development is paused pending reassessment, not abandoned.
Longevity Applications Context
The longevity relevance of SS-31 is conceptually compelling even if clinical translation is uncertain:
- Mitochondrial dysfunction is considered one of the hallmarks of aging (Lopez-Otin 2013)
- Cardiolipin decline specifically is documented in aging human cardiac and skeletal muscle
- SS-31 is the only known compound that directly targets this specific aging mechanism
- Animal aging studies show restoration of youthful mitochondrial function parameters
- Speculative longevity use focuses on sub-clinical cardiovascular aging, skeletal muscle function preservation, and metabolic efficiency
Frequently Asked Questions
What does SS-31 do for mitochondria?
SS-31 targets and binds cardiolipin — the key phospholipid of the inner mitochondrial membrane — preventing its oxidation. This protects the cristae structure supporting the electron transport chain, improving energy production efficiency and reducing reactive oxygen species from mitochondrial dysfunction.
Is SS-31 in human clinical trials?
Yes. Elamipretide (SS-31) has undergone Phase II and III trials for heart failure with reduced ejection fraction (MMAD trial). The primary endpoint was not met but secondary endpoints showed functional improvements. Additional trials continue for heart failure with preserved EF (PIROUETTE) and kidney disease (SPIRO).
Explain the SS-31 cardiolipin mechanism.
Cardiolipin is unique to the inner mitochondrial membrane and is essential for cristae formation. SS-31's alternating cationic and aromatic residues allow it to concentrate in the IMM and directly bind cardiolipin, preventing its peroxidation and maintaining cristae structure and electron transport chain efficiency.
SS-31 vs other mitochondrial supplements — how does it compare?
SS-31 is unique in directly targeting cardiolipin — no other known compound does this. CoQ10 supports ETC electron transfer. Alpha-lipoic acid is a mitochondrial antioxidant. MitoQ is a mitochondria-targeted antioxidant. SS-31 works upstream at the structural level, potentially more fundamentally addressing mitochondrial aging.